ClinicalTrials.gg
Enrolling by invitationNCT06445673TripleTRE-NISUpdated Oct 29, 2026

A Prospective Non-interventional Observational Study to Observe Long-term Treatment and Outcomes in Pulmonary Arterial Hypertension (PAH) Patients

An observational study in Pulmonary Arterial Hypertension, sponsored by AOP Orphan Pharmaceuticals AG. Enrolling by invitation at 18 sites in 9 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-29.

Sponsored by AOP Orphan Pharmaceuticals AG · Observational

How we know

Updated Oct 29, 20263 sites added3 sites removedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
110
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 119 studies in Pulmonary Arterial Hypertension with a site in Germany — 13 open to participants now, 18 under way, 7 of them phase 3. Pulmonary Arterial Hypertension · Germany.

Planned enrollment
10th of 17
110 · median 120
Started
2024
with 6 others
Observational
17 of 119
4 open now
Primary completion
2030-06
later than 17 of 17 live
Registered
111th of 119
by date

Among the 119 studies in Pulmonary Arterial Hypertension with a site in Germany, this one is the 10th largest by planned enrollment of the 17 observational ones that give a count, is one of 7 that started in 2024, is one of 17 observational ones, reaches primary completion later than 17 of the 17 other live ones, and was the 111th registered.

Pulmonary Arterial Hypertension

701 studies on the registry are indexed under Pulmonary Arterial Hypertension; 141 are open to participants now.

Browse Pulmonary Arterial Hypertension studies →

Open to participants now

13 of the 119 studies in Pulmonary Arterial Hypertension with a site in Germany are open now. Recruiting first, the newest first:

7 more — sign in →

All 13 open studies →

A study can be open while its sites in Germany have not opened yet or have stopped. Only those recruiting at a site in Germany →

Who these studies take

Of the 90 Pulmonary Arterial Hypertension studies recruiting now, 51 (57%) set no upper age limit and 24 (27%) stop at 75 or younger; 18 take children under 18; 11 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 119 studies in Pulmonary Arterial Hypertension with a site in Germany, or all of them as a file.
02

Study summary

The goal of this observational study is to learn about the long-term development and outcomes of different treatment patterns of patients who initially participated in the TripleTRE study.

The primary objective of this non-interventional follow-up study is to assess the long-term real-world clinical outcomes, including disease progression and survival rates, in patients who initially participated in and completed the randomized TripleTRE trial.

Planned observation duration per patient is a minimum of 3 years.

03

Conditions studied

  • Pulmonary Arterial Hypertension
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

The study population will consist of patients who participated in the TripleTRE study and who have not been lost to follow-up and have given a written informed consent for their participation in the NIS.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

1. Patients previously participating in the randomized TripleTRE trial who are able and willing to provide a signed for study participation in NIS

Exclusion criteria

Exclusion Criteria:

  1. Lost to follow-up patients of TripleTRE study
  2. Patients who discontinued all medicinal PAH treatments (e.g. after successful lung transplantation)
  3. Patients who withdrew from the initial TripleTRE trial due to significant non-compliance with trial requirements (not adhering to therapy, not coming to hospital visits)
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
110 participants (estimated)
Patient registry
No

Groups and cohorts

  • TripleTRE NIS patients

    all patients previously treated within the TripleTRE trial who are willing to participate in this NIS

06

What researchers measure

Primary outcomes

  1. Time to death or lung transplantation

    Time frame: up to year 3

  2. Time to first clinical worsening

    clinical worsening is defined as fulfilling on of the following criteria: * PAH related death (including all deaths where PAH cannot be excluded as cause) * Lung transplantation due to PAH * PAH-related hospitalization * Post baseline decrease in 6MWD by 15% * Post baseline worsening of WHO FC

    Time frame: up to year 3

  3. Total number of clinical worsenings

    clinical worsening is defined as fulfilling on of the following criteria: * PAH related death (including all deaths where PAH cannot be excluded as cause) * Lung transplantation due to PAH * PH-related hospitalization * Post baseline decrease in 6MWD by 15% * Post baseline worsening of WHO FC

    Time frame: up to year 3

Secondary outcomes

  1. Long-term change in 6MWD

    6-Minute Walking Distance (6MWD) will be measured in meters

    Time frame: up to year 3

  2. Long-term change in PAH treatment regimens

    any change or addition of new PH medication including dosing in time

    Time frame: up to year 3

  3. Long-term change in risk status

    Risk status measured by simplified four-strata risk-assessment tool

    Time frame: up to year 3

  4. Long-term change in WHO FC

    World Health Organization Functional Class (WHO FC) is categorized from I (no symptoms) to IV (severe dyspnea and symptoms)

    Time frame: up to year 3

  5. Long-term change in BDS

    BDS - Borg Dyspnea Score, ranging from 0 (no exertion) to 10 (maximum)

    Time frame: up to year 3

  6. Long-term change in NT-proBNP/BNP

    NT-proBNP/BNP: N-terminal pro Brain Natriuretic Peptide

    Time frame: up to year 3

  7. Long-term change in Pulmonary Vascular Resistance (PVR)

    PVR to be measured in WU Parameter will be collected according to clinical routine

    Time frame: up to year 3

  8. Long-term change in mean Pulmonary Arterial Pressure (mPAP)

    mPAP to be measured in mmHg Parameter will be collected according to clinical routine

    Time frame: up to year 3

  9. Long-term change in Right Atrial Pressure (RAP)

    RAP to be measured in mmHg Parameter will be collected according to clinical routine

    Time frame: up to year 3

  10. Long-term change in mean Right Atrial Pressure (mRAP)

    mean Right Atrial Pressure (mRAP) to be measured in mmHg Parameter will be collected according to clinical routine

    Time frame: up to year 3

  11. Long-term change in Cardiac Index (CI)

    Cardiac index (CI) measured in liters per minute per square meter Parameter will be collected according to clinical routine

    Time frame: up to year 3

  12. Long-term change in Cardiac Output (CO)

    Cardiac output (CO) measured in liters per minute Parameter will be collected according to clinical routine

    Time frame: up to year 3

  13. Long-term change in Pulmonary capillary wedge pressure (PCWP)

    Pulmonary capillary wedge pressure (PCWP) measured in mmHg Parameter will be collected according to clinical routine

    Time frame: up to year 3

  14. Long-term change in Stroke volume index (SVI)

    Parameter will be collected according to clinical routine

    Time frame: up to year 3

  15. Long-term change in RV-PA coupling

    RV-PA coupling estimated by the ratio of tricuspid annular plane systolic excursion by pulmonary artery systolic pressure Parameter will be collected according to clinical routine

    Time frame: up to year 3

  16. Long-term change in RV end-diastolic area (RVEDA)

    RV end-diastolic area (RVEDA) measured in square centimeters Parameter will be collected according to clinical routine

    Time frame: up to year 3

  17. Long-term change in RV end-systolic area (RVESA)

    RV end-systolic area (RVESA) measured in square centimeters Parameter will be collected according to clinical routine

    Time frame: up to year 3

  18. Long-term change in RV fractional area change (RVFAC)

    RV fractional area change (RVFAC) calculated in % Parameter will be collected according to clinical routine

    Time frame: up to year 3

  19. Long-term change in Right Atrium (RA) area

    Right Atrium (RA) area in square centimeters Parameter will be collected according to clinical routine

    Time frame: up to year 3

  20. Long-term change in Pericardial effusion

    Pericardial effusion assessment will be done and rated as yes/no Parameter will be collected according to clinical routine

    Time frame: up to year 3

  21. Long-term change in Right ventricular ejection fraction (RVEF)

    Parameter will be collected according to clinical routine

    Time frame: up to year 3

Other outcomes

  1. Frequency and seriousness of adverse events (AE) and adverse drug reactions (ADR)

    This includes: * Adverse events (S)AEs * Adverse drug reactions (S)ADRs related to any of PAH treatments * Adverse events related to underlying diagnosis, PAH

    Time frame: up to year 3

  2. Long-term change in QoL using European Quality of Life 5 Dimensions 5 Level Version (EQ-5D-5L) questionnaire

    The EQ-5D-5L questionnaire consists of 2 parts - the EQ-5D-5L descriptive system and the EQ Visual Analogue scale. The descriptive system comprises 5 dimensions (mobility, self-care, usual activities, pain/discomfort, anxiety/depression). Each dimension has 5 levels: no problems, slight problems, moderate problems, severe problems and extreme problems. The patient is asked to indicate his/her health state by ticking (or placing a cross) in the box against the most appropriate statement in each of the 5 dimensions. This decision results in a 1-digit number expressing the level selected for that dimension. The digits for 5 dimensions can be combined in a 5-digit number describing the respondent's health state. It should be noted that the numerals 1-5 have no arithmetic properties and should not be used as a cardinal score.

    Time frame: up to year 3

  3. Long-term change in QoL using PAH-specific emPHasis-10 questionnaire

    Emphasis meaning something of special importance or significance. Please translate using the most appropriate term. The PH in emPHasis represents the condition Pulmonary Hypertension. The number 10 refers to the number of items in the questionnaire. This questionnaire is designed to determine how Pulmonary Hypertension (PH) affects patient's life. It refers to how PH affects or the impact that PH has on the patient's life.

    Time frame: up to year 3

07

Study locations

18 sites
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jul 2024 (actual). Primary completion is estimated for Jun 2030, 71 months after the start.

Of 85 observational studies under Pulmonary Arterial Hypertension, half reached primary completion within 58 months of starting (the median), counting those still running; a quarter within 30 and three quarters within 93. This study's planned 71 months is above that.

How these figures are worked out, and which studies are left out of them.

Registered
May 29, 2024
First posted
Jun 6, 2024
StartActual
Jul 31, 2024
Primary completionEst.
Jun 2030
CompletionEst.
Jun 2030
Last update
Oct 29, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
3 sites added, 3 sites removed
Show 3 added (1 Czechia, 1 Poland, 1 Romania)
  • Všeobecná fakultní nemocnice v Praze · Prague, Czechia
  • John Paul II Hospital Krakow · Krakow, Poland
  • Emergency Clinical County Hospital of Targu Mures · Târgu Mureş, Romania
Show 3 removed
  • Všeobecná fakultní nemocnice v Praze · Praha, Czechia
  • John Paul II Hospital Krakow · Kraków, Poland
  • Emergency Clinical County Hospital of Targu Mures · Târgu-Mureş, Romania
Oct 29, 2026
Show all 1 update
  1. Oct 29, 2026
    3 sites added, 3 sites removed
    Show 3 added (1 Czechia, 1 Poland, 1 Romania)
    • Všeobecná fakultní nemocnice v Praze · Prague, Czechia
    • John Paul II Hospital Krakow · Krakow, Poland
    • Emergency Clinical County Hospital of Targu Mures · Târgu Mureş, Romania
    Show 3 removed
    • Všeobecná fakultní nemocnice v Praze · Praha, Czechia
    • John Paul II Hospital Krakow · Kraków, Poland
    • Emergency Clinical County Hospital of Targu Mures · Târgu-Mureş, Romania
    + 3 other changes: verification date, criteria formatting and index terms

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06445673
Lead sponsor
AOP Orphan Pharmaceuticals AG
Responsible party
Sponsor
First posted
Jun 6, 2024
Start date
Jul 31, 2024
Primary completion
Jun 2030 (estimated)
Completion
Jun 2030 (estimated)
Last update
Oct 29, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion